Terms: = Leukemia AND PIM1, PIM, 5292, ENSG00000137193, P11309
314 results:
1. pim Kinases as Potential Biomarkers and Therapeutic Targets in Inflammatory Arthritides.
Assirelli E; Ciaffi J; Scorcu V; Naldi S; Brusi V; Mancarella L; Lisi L; Pignatti F; Ursini F; Neri S
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542097
[TBL] [Abstract] [Full Text] [Related]
2. Synthesis, kinase inhibition and anti-leukemic activities of diversely substituted indolopyrazolocarbazoles.
Frazier T; Pereira E; Aesoy R; Nauton L; Giraud F; Herfindal L; Anizon F; Moreau P
Eur J Med Chem; 2024 Apr; 269():116352. PubMed ID: 38537512
[TBL] [Abstract] [Full Text] [Related]
3. pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
Lee JK; Chatterjee A; Scarpa M; Bailey CM; Niyongere S; Singh P; Mustafa Ali MK; Kapoor S; Wang Y; Silvestri G; Baer MR
Cancer Res Commun; 2024 Feb; 4(2):431-445. PubMed ID: 38284896
[TBL] [Abstract] [Full Text] [Related]
4. Identification and assessment of new pim2 inhibitors for treating hematologic cancers: A combined approach of energy-based virtual screening and machine learning evaluation.
Chen X; Zhao J; Chen R; Shen L; Lu J; Guo Y; Chi X; Geng S; Zhang Q; Pan Z; He X; Xu L; Shen Z; Yang H; Lei T
Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300516. PubMed ID: 38263717
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive Insights that Targeting pim for Cancer Therapy: Prospects and Obstacles.
Chen L; Mao W; Ren C; Li J; Zhang J
J Med Chem; 2024 Jan; 67(1):38-64. PubMed ID: 38164076
[TBL] [Abstract] [Full Text] [Related]
6. Corynoline inhibits esophageal squamous cell carcinoma growth via targeting pim-3.
Shi Y; Yuan Q; Chen Y; Li X; Zhou Y; Zhou H; Peng F; Jiang Y; Qiao Y; Zhao J; Zhang C; Wang J; Liu K; Dong Z
Phytomedicine; 2024 Jan; 123():155235. PubMed ID: 38128397
[TBL] [Abstract] [Full Text] [Related]
7. Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system.
Jedlowski PM; DuPont JP
J Eur Acad Dermatol Venereol; 2024 May; 38(5):937-944. PubMed ID: 38071595
[TBL] [Abstract] [Full Text] [Related]
8. pim kinases regulate early human Th17 cell differentiation.
Buchacher T; Shetty A; Koskela SA; Smolander J; Kaukonen R; Sousa AGG; Junttila S; Laiho A; Rundquist O; Lönnberg T; Marson A; Rasool O; Elo LL; Lahesmaa R
Cell Rep; 2023 Dec; 42(12):113469. PubMed ID: 38039135
[TBL] [Abstract] [Full Text] [Related]
9. KZ02 enhances the radiosensitivity of BRAF-mutated CRC in vitro and in vivo.
Guo Y; Li X; Yuan R; Ren J; Huang Y; Yu Y; Tian H
Eur J Pharmacol; 2023 Nov; 959():176060. PubMed ID: 37775019
[TBL] [Abstract] [Full Text] [Related]
10. Design, synthesis, and evaluation of a mitoxantrone probe (MXP) for biological studies.
Wallin S; Singh S; Borgstahl GEO; Natarajan A
Bioorg Med Chem Lett; 2023 Oct; 94():129465. PubMed ID: 37669721
[TBL] [Abstract] [Full Text] [Related]
11. IGH 3'RR recombination uncovers a non-germinal center imprint and c-MYC-dependent IGH rearrangement in unmutated chronic lymphocytic leukemia.
Al Jamal I; Parquet M; Guiyedi K; Aoufouchi S; Le Guillou M; Rizzo D; Pollet J; Dupont M; Boulin M; Faumont N; Boutouil H; Jardin F; Ruminy P; El Hamel C; Lerat J; Al Hamaoui S; Makdissy N; Feuillard J; Gachard N; Peron S
Haematologica; 2024 Feb; 109(2):466-478. PubMed ID: 37496419
[TBL] [Abstract] [Full Text] [Related]
12. Phase 1/2 Study of the Pan-pim Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.
Patel MR; Donnellan W; Byrne M; Asch AS; Zeidan AM; Baer MR; Fathi AT; Kuykendall AT; Zheng F; Walker C; Cheng L; Marando C; Savona MR
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):674-686. PubMed ID: 37290996
[TBL] [Abstract] [Full Text] [Related]
13. Targeting BET Proteins Downregulates miR-33a To Promote Synergy with pim Inhibitors in CMML.
Letson CT; Balasis ME; Newman H; Binder M; Vedder A; Kinose F; Ball M; Kruer T; Quintana A; Lasho TL; Finke CM; Almada LL; Grants JM; Zhang G; Fernandez-Zapico ME; Gaspar-Maia A; Lancet J; Komrokji R; Haura E; Sallman DA; Reuther GW; Karsan A; Rix U; Patnaik MM; Padron E
Clin Cancer Res; 2023 Aug; 29(15):2919-2932. PubMed ID: 37223910
[TBL] [Abstract] [Full Text] [Related]
14. Targeting pim kinases in hematological cancers: molecular and clinical review.
Bellon M; Nicot C
Mol Cancer; 2023 Jan; 22(1):18. PubMed ID: 36694243
[TBL] [Abstract] [Full Text] [Related]
15. Discovery of new pyridine-quinoline hybrids as competitive and non-competitive pim-1 kinase inhibitors with apoptosis induction and caspase 3/7 activation capabilities.
El-Miligy MMM; Abdelaziz ME; Fahmy SM; Ibrahim TM; Abu-Serie MM; Mahran MA; Hazzaa AA
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2152810. PubMed ID: 36629075
[TBL] [Abstract] [Full Text] [Related]
16. Synthesis of new pyrazolo[4,3-a]phenanthridine pim-1 inhibitors and evaluation of their cytotoxic activity towards the MOLM-13 acute myeloid leukemia cell line.
Auvert E; Aesoy R; Giraud F; Herfindal L; Anizon F; Moreau P
Bioorg Med Chem Lett; 2022 Oct; 73():128914. PubMed ID: 35917834
[TBL] [Abstract] [Full Text] [Related]
17. Stabilization of pim Kinases in Hypoxia Is Mediated by the Deubiquitinase USP28.
Toth RK; Solomon R; Warfel NA
Cells; 2022 Mar; 11(6):. PubMed ID: 35326457
[TBL] [Abstract] [Full Text] [Related]
18. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Smith M; Dai A; Ghilardi G; Amelsberg KV; Devlin SM; Pajarillo R; Slingerland JB; Beghi S; Herrera PS; Giardina P; Clurman A; Dwomoh E; Armijo G; Gomes ALC; Littmann ER; Schluter J; Fontana E; Taur Y; Park JH; Palomba ML; Halton E; Ruiz J; Jain T; Pennisi M; Afuye AO; Perales MA; Freyer CW; Garfall A; Gier S; Nasta S; Landsburg D; Gerson J; Svoboda J; Cross J; Chong EA; Giralt S; Gill SI; Riviere I; Porter DL; Schuster SJ; Sadelain M; Frey N; Brentjens RJ; June CH; Pamer EG; Peled JU; Facciabene A; van den Brink MRM; Ruella M
Nat Med; 2022 Apr; 28(4):713-723. PubMed ID: 35288695
[TBL] [Abstract] [Full Text] [Related]
19. pim2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma.
Haas M; Caron G; Chatonnet F; Manenti S; Alaterre E; Devin J; Delaloy C; Bertolin G; Viel R; Pignarre A; Llamas-Gutierrez F; Marchalot A; Decaux O; Tarte K; Delpy L; Moreaux J; Fest T
Blood; 2022 Apr; 139(15):2316-2337. PubMed ID: 35108359
[TBL] [Abstract] [Full Text] [Related]
20. Relationship between the transcriptional expression of pim1 and local control in patients with head and neck squamous cell carcinomas treated with radiotherapy.
León X; García J; Pujol A; de Juan J; Vásquez R; Quer M; Camacho M
Eur Arch Otorhinolaryngol; 2022 Jul; 279(7):3679-3684. PubMed ID: 34993612
[TBL] [Abstract] [Full Text] [Related]
[Next]
